Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) Chairman P Roy Vagelos sold 8,028 shares of the company’s stock on the open market in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $340.01, for a total value of $2,729,600.28. Following the sale, the chairman now directly owns 248,540 shares of the company’s stock, valued at approximately $84,506,085. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on REGN. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Regeneron Pharmaceuticals has an average rating of “Buy” and an average price target of $345.94.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 351.775 on Monday. Regeneron Pharmaceuticals has a 52 week low of $227.64 and a 52 week high of $352.49. The stock has a 50-day moving average of $316. and a 200-day moving average of $308.5. The company has a market cap of $35.315 billion and a price-to-earnings ratio of 99.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $10.14 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.